Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Farhat Nasim

      Articles By : Farhat Nasim

      Aurobindo Pharma gets USFDA warning letter for Andhra Pradesh unit

      Aurobindo Pharma gets USFDA warning letter for Andhra Pradesh unit

      Farhat Nasim21 Jun 2019 12:29 PM IST
      The company has received a warning letter from the United States Food and Drug Administration (USFDA) relating to our unit XI, active pharmaceutical...
      Sanofi to slash 466 jobs as part of R&D restructure

      Sanofi to slash 466 jobs as part of R&D restructure

      Farhat Nasim21 Jun 2019 10:47 AM IST
      The 466 job cuts are to be implemented on a voluntary basis, Sanofi said. The company currently employs 15,000 in R&D worldwide out of total...
      Bayer Stivarga becomes first drug to be tested in brain cancer patients in multi-arm cooperation trial

      Bayer Stivarga becomes first drug to be tested in brain cancer patients in multi-arm cooperation trial

      Farhat Nasim21 Jun 2019 9:15 AM IST
      Bayer's Stivarga will be the first drug to be evaluated in this trial.New Delhi: Bayer announced today that the Stivarga (regorafenib) arm of the...
      Fortis Drops plan to sell stake in RHT Health Trust, RHTTM

      Fortis Drops plan to sell stake in RHT Health Trust, RHTTM

      Farhat Nasim18 Jun 2019 1:57 PM IST
      New Delhi: Country's one of the leading super speciality hospital chain, Fortis Healthcare (FHL) has recently scrapped the plan to sell stakes in RHT...
      Caplin Point gets 2 USFDA observations for sterile injectable site in Chennai

      Caplin Point gets 2 USFDA observations for sterile injectable site in Chennai

      Farhat Nasim17 Jun 2019 1:46 PM IST
      The US Food and Drug Administration (USFDA) has completed inspection of Caplin Steriles Ltd's site at Gummidipoondi in Tamil Nadu, between June 6-14,...
      25 batches of drugs including Paracetamol, Ciprofloxacin of 18 pharma firms found substandard

      25 batches of drugs including Paracetamol, Ciprofloxacin of 18 pharma firms found substandard

      Farhat Nasim17 Jun 2019 12:16 PM IST
      Painkiller Nimesulide and anti-fever medicine Paracetamol of Navketan Pharma and Nestor Pharmaceuticals, respectively, were found to be substandard by...
      Lupin recalls over 18000 bottles of Cefdinir for Oral Suspension in US

      Lupin recalls over 18000 bottles of Cefdinir for Oral Suspension in US

      Farhat Nasim17 Jun 2019 10:58 AM IST
      Cefdinir is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the...
      Aurobindo Pharma lines up over Rs 1395 crore capex for FY20

      Aurobindo Pharma lines up over Rs 1395 crore capex for FY20

      Farhat Nasim17 Jun 2019 10:00 AM IST
      "Around USD 200 million is what we are targeting (on capex in FY20)...Capex for biosimilar may not be a huge one for FY20. The majority of the CAPEX...
      Drugmakers file lawsuit against Government regulation requiring drug prices in TV ads

      Drugmakers file lawsuit against Government regulation requiring drug prices in TV ads

      Farhat Nasim17 Jun 2019 9:15 AM IST
      Drugmakers have argued against the regulation, saying list prices do not reflect the final price paid by patients as it excludes rebates and discounts...
      Cipla moves against NPPA for price fixation of asthma drugs; DOP junks plea

      Cipla moves against NPPA for price fixation of asthma drugs; DOP junks plea

      Farhat Nasim16 Jun 2019 11:44 AM IST
      New Delhi: Mumbai-based drugmaker, Cipla Limited's review petition against the Government regulatory agency, National Pharmaceutical Pricing Authority...
      Laurus Labs gets 2 USFDA observations for  its API facilities in Visakhapatnam

      Laurus Labs gets 2 USFDA observations for its API facilities in Visakhapatnam

      Farhat Nasim16 Jun 2019 9:35 AM IST
      "This is a regular surveillance audit by USFDA, and no data integrity issues were observed in the inspection," Laurus Labs added.New Delhi: Drugmaker...
      Novartis India appoints Sanjay Murdeshwar as Vice Chairman, Managing Director

      Novartis India appoints Sanjay Murdeshwar as Vice Chairman, Managing Director

      Farhat Nasim16 Jun 2019 9:31 AM IST
      Sanjay Murdeshwar is Country President, Novartis in India and responsible for the company's pharmaceuticals business in the country.New Delhi: Pharma...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok